Avid Bioservices, Inc.

JASPER, Ind.--(BUSINESS WIRE)--Kimball Electronics, Inc. (Nasdaq: KE) today announced the Company acquired Helvoet Polymer Technologies B.V. (“Helvoet”), a Contract Development and Manufacturing Organization (CDMO), based in Europe and with operations in India focused on microfluidics, diagnostics, and drug delivery. The transaction was valued at a purchase price of €90 million (excluding working capital, other customary adjustments, and acquisition-related costs), or approximately $103 million.

businesswire.com - 2026-07-01 02:00:00

Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits PR Newswire MUMBAI,

gurufocus.com - 2026-06-22 05:00:00

BLUE ASH, Ohio, June 18, 2026 (GLOBE NEWSWIRE) -- Resilience, along with Ohio Governor Mike DeWine, JobsOhio, the City of Blue Ash, and REDI Cincinnati, today announced the relocation of Resilience's corporate headquarters from San Diego, California to Blue Ash, Ohio, a northern suburb of Cincinnati. Resilience is a leading biomanufacturing contract and development manufacturing organization (CDMO) dedicated to broadening access to complex medicines, with a large drug product manufacturing facility in West Chester, Ohio. This move strengthens the company's operational footprint in the state, and reinforces Ohio's position as a growing hub for pharmaceutical and sterile manufacturing innovation.

globenewswire.com - 2026-06-18 09:05:00

MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc's Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO (Contract Development and Manufacturing Organization) in preparation for the upcoming production of the Company's lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid tumors.

globenewswire.com - 2026-06-16 08:45:00

Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures

gurufocus.com - 2026-06-11 08:00:00

JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended March 31, 2026 and provided a corporate update.

prnewswire.com - 2026-06-10 07:55:00

MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEMÂ in the U.S.

gurufocus.com - 2026-06-04 00:00:00

JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd.

prnewswire.com - 2026-05-20 07:00:00

MELBOURNE, Australia, May 19, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that a Contract and Development Manufacturing Organization (CDMO) has been engaged for the GMP manufacture of the Company's lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid tumors. Based in Europe, the CDMO provides end-to-end services for preclinical and clinical projects, with extensive experience in decoding biologics production (plasmid DNA and recombinant proteins) providing services of cell line generation, banking and characterization, analytical development, process development and batches production of both drug substances and drug products (decoding biologics production refers to the specialized process of understanding, optimizing, and controlling the manufacturing of complex medicines derived from living cells, such as proteins, vaccines, and monoclonal antibodies).

globenewswire.com - 2026-05-19 08:45:00

Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% YoY VINIA brand customer base grows to 90,000 active users as of the end of April Two-lens framework enacted in Q1 to optimize performance across CDMO and D2C businesses Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 14, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced its first quarter 2026 financial results. The Company will hold a conference call this morning at 8:00 am Eastern Daylight Time (EDT) to discuss the results and provide an update on business operations.

newsfilecorp.com - 2026-05-14 07:00:00

Business development appointment is aligned with securing long-term customers for development and manufacturing partnerships Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms. Salzman-Frenkel's role will be instrumental for sourcing and managing new prospective contracts across the pharmaceutical, nutraceutical, nutrition, and cosmetic areas for BioHarvest's contract development and manufacturing organization (CDMO) business.

newsfilecorp.com - 2026-05-13 17:32:00

Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility PR Newswire

gurufocus.com - 2026-05-13 11:00:00

CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:  LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at CDMO Live Europe.

globenewswire.com - 2026-05-12 16:05:00

Source plant is widely regarded as one of the most valuable fragrance raw materials in the world Stage 2 contract follows successful Stage 1 completion in March 2026 Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 12, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has signed a $1.2 million-dollar Stage 2 contract as part of a multi-stage development program for a rare scent-producing plant used in the global fragrance industry. This scent is widely regarded as one of the most valuable fragrance raw materials in the world, with premium grades commanding prices exceeding tens of thousands of U.S. dollars per kilogram and demand growing across the Middle East, Asia, and luxury Western perfume markets.

newsfilecorp.com - 2026-05-12 07:30:00

LIMERICK, Ireland, April 28, 2026 (GLOBE NEWSWIRE) -- kneat.com, inc. (TSX: KSI) (OTCQX: KSIOF), the global leader in digital validation and quality process automation, today announced that it has signed a Master Subscription Agreement with one of Europe's largest Contract Development and Manufacturing Organizations (“CDMO”) to digitize their equipment validation processes.

globenewswire.com - 2026-04-28 17:06:00